AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03189212 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Visit
Description: Routine 6-month follow up appointment at the NYULMC transplant center
Study NCT03189212 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemedicine Visit
Description: TM visit conducted at the patient's dialysis unit as a replacement to usual 6 month routine f/u visit
Study NCT01703390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI + Cetuximab
Study NCT01703390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: modifiedFOLFOX6 + Cetuximab
Study NCT03423212 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Just Do You
Description: Just Do You is an intervention designed to keep young adults connected to their professional behavioral health treatments. It is a brief two-module engagement program that utilizes a hybrid provider team of a licensed clinician and peer to increase young adult engagement in adult outpatient day programs (i.e., New York State Personalized Recovery Oriented Services). The first session consists of the following components: 1) Welcome; Group Guidelines, Purpose, 2) Discuss Recovery Principles; Narrative of Role Model; 3) Video of Celebrity Service User and Discussion, and 4) Recovery Goals (and role of services in that). The second session consists of: 1) What are services \& how can they help? 2) Visual art exercise -- Cause of SMI and validation, 3) Maintaining my Medicaid Insurance, and 4) Discussion of Systemic Barriers.
Study NCT03423212 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: The active control condition will receive the PROS program that is standard in the agencies, and a two-session curriculum on maintaining healthy relationships, which is an identified issue for the population.
Study NCT03788161 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Real Virtual Reality
Description: Participants will receive a distraction by playing a game of virtual reality with a 3D application
Study NCT03788161 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Virtual Reality
Description: Participants will receive a placebo distraction with a game of virtual reality with a 3D application without functioning
Study NCT03296969 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cesarean section
Description: All women underwent Pfnannenstiel incision under general or spinal anaesthesia, with a combination of sharp and blunt dissection to open the abdomen. The rectus muscles are dissected off the fascia, and the muscles are separated in the midline by pulling. Then the uterus is opened followed by fetal and placental extraction. The transverse lower uterine segment incision is closed in two layers of continuous Vicryl number 1 suture. The parietal peritoneum is closed using a continuous absorbable suture. In group (A): rectus muscle re-approximation is done by 3 interrupted sutures, but muscle is not closed in the other group. The rectus sheath is sutured using continuous absorbable sutures. Finally, skin is sutured with subcuticular sutures with Vicryl Rapide
Study NCT03296969 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rectus muscle approximation
Description: aprroximation of the lower parts of rectus abdomius muscles during cesarean section
Study NCT01255072 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: 20 Sham daily sessions:25 trains, 10seconds at 5Hz, train interval of 25 seconds (time off). Target: left dorsolateral prefrontal cortex.
Study NCT01255072 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: 20 daily sessions: each one with 25 trains of 10seconds at 5Hz, train interval of 25 seconds (time off), pulse intensity corrected based on atrophy degree by a specific correction formule. Target: left dorsolateral prefrontal cortex.
Study NCT01131559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisdexamfetamine
Description: Oral; 20-70mg/day
Study NCT01131559 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Oral; 20-70mg/day
Study NCT04226300 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic
Description: A transversus abdominis nerve block will be placed laparoscopically.
Study NCT04226300 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: A transversus abdominis nerve block will be place by ultrasound
Study NCT05856253 — intervention group
Intervention type: PROCEDURE
Intervention: Enhanced recovery program
Description: Recvoery programs includes specific measures validated in multidisciplinary consultation, spread over the pre- intra- and postoperative period.
Study NCT01519817 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-6301 (Yeast Brachyury Vaccine)
Description: GI-6301 is a heat-killed, recombinant yeast-based vaccine engineered to express the transcription factor, Brachyury. The Brachyury gene is used to transfect the parental yeast strain (S. cerevisiae W303 - a haploid strain with known mutations from wildtype yeast) to produce the final recombinant vaccine product.
Study NCT01089842 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health coaching
Description: Coaching based advice will be performed by previously trained nurses. Intervention will be directed to increase physical activity to achieve levels recommended on guidelines. Patients will receive one session per month during 6 months. Time for each session is estimated on 10 to 20 minutes. Sessions will be mostly carried out by phone, although physical attendance or internet services can also be used.
Study NCT01089842 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Usual care
Description: Patients on control group will receive usual assistance, including physical activity counselling by their treating physician.
Study NCT04020653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid hydrochloride (5-ALA HCl) 600 mg QD
Description: 5-ALA HCl 150 mg capsules will be given to the patients as 600 mg QD
Study NCT04020653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium ferrous citrate (SFC) 472 mg QD
Description: SFC 118 mg capsules will be given to the patients as 472 mg QD
Study NCT04020653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemisinin-based combination (ACT)
Description: Tablets of ACT will be administered following Dosage and Administration in the package insert of ACT. ACT will be supplied as a combination tablet.
Study NCT04020653 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Artemisinin-based combination (ACT)
Description: Tablets of ACT will be administered following Dosage and Administration in the package insert of ACT. ACT will be supplied as a combination tablet.
Study NCT04020653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo capsules to 5-ALA HCl and SFC will be administered to the patients
Study NCT04020653 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules to 5-ALA HCl and SFC will be administered to the patients
Study NCT04020653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid hydrochloride (5-ALA HCl) 300 mg BID
Description: 5-ALA HCl 150 mg capsules will be given to the patients as 300 mg BID
Study NCT04020653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium ferrous citrate (SFC) 236 mg BID
Description: SFC 118 mg capsules will be given to the patients as 236 mg BID
Study NCT02650713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6958688
Description: RO6958688 is administered by IV infusion~In Part IA: RO6958688 is administered weekly (QW) on days 1,8 and 15 of each 21-day cycle.~In Part 1b: RO6958688 is administered weekly (QW) or every 3 weeks (Q3W). Cohort A: RO6958688 starting dose will be 100 mg either QW or Q3W.~Step Up dose cohorts: RO6958688 starting dose will be 40mg and increase with each administration up to the MTD or 1200 mg whichever is lower.
Study NCT01151306 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: Simvastatin 20mg once daily (in the evening) for 6 weeks
Study NCT01151306 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactose tablet
Description: One tablet taken each evening for 6 weeks
Study NCT00612911 — intervention group
Intervention type: OTHER
Intervention: Cell therapy
Description: bone marrow mononuclear cell
Study NCT03784391 — intervention group
Intervention type: DRUG
Intervention: Lampit (Nifurtimox, BAYA2502)
Description: Nifurtimox is a drug already approved in some South American countries since more than 45 years
Study NCT02653157 — intervention group
Intervention type: OTHER
Intervention: MDR-GNB
Study NCT04230369 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure-based Internet-CBT
Description: Internet-CBT for anxiety-related asthma 8 weekly modules of CBT delivered over the internet and targeting enhanced function and decreased symptoms of anxiety. Participants work independently from home with the treatment and receive support from experienced Internet-CBT Psychologists through written messages in the secure platform. All participants in both conditions can use any other available treatment (TAU), but psychological, from pre-assessments to 2 months after treatment completion.
Study NCT04230369 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as usual
Description: Patients randomized to treatment as usual will receive the same medical information that participants in the Internet-CBT get, with physiological information about asthma and the importance of medical adherence to achieve well controlled asthma, but without the exposure-based treatment and no therapist support. All participants in both conditions can use any other available treatment (TAU), but psychological, from pre-assessments to 2 months after treatment completion.
Study NCT00281697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: The dose of bevacizumab was based on a patient's weight at baseline and remained the same throughout the study.
Study NCT00281697 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00281697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard chemotherapy
Description: Patients received one of the following four standard chemotherapies for metastatic breast cancer.~1. Taxane - Paclitaxel (Taxol) 90 mg/m\^2 IV every week for 3 weeks followed by 1 week of rest; paclitaxel (Taxol) 175 mg/m\^2 IV every 3 weeks, or paclitaxel protein-bound particles (Abraxane) 260 mg/m\^2 IV every 3 weeks; or docetaxel (Taxotere) 75-100 mg/m\^2 IV every 3 weeks.~2. Gemcitabine (Gemzar) 1250 mg/m\^2 IV on Days 1 and 8 of each 3-week cycle.~3. Vinorelbine (Navelbine) 30 mg/m\^2 IV every week of each 3-week cycle.~4. Capecitabine (Xeloda) 1000 mg/m\^2 orally twice daily on Days 1-14 of each 3-week cycle.
Study NCT00281697 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard chemotherapy
Description: Patients received one of the following four standard chemotherapies for metastatic breast cancer.~1. Taxane - Paclitaxel (Taxol) 90 mg/m\^2 IV every week for 3 weeks followed by 1 week of rest; paclitaxel (Taxol) 175 mg/m\^2 IV every 3 weeks, or paclitaxel protein-bound particles (Abraxane) 260 mg/m\^2 IV every 3 weeks; or docetaxel (Taxotere) 75-100 mg/m\^2 IV every 3 weeks.~2. Gemcitabine (Gemzar) 1250 mg/m\^2 IV on Days 1 and 8 of each 3-week cycle.~3. Vinorelbine (Navelbine) 30 mg/m\^2 IV every week of each 3-week cycle.~4. Capecitabine (Xeloda) 1000 mg/m\^2 orally twice daily on Days 1-14 of each 3-week cycle.
Study NCT03498729 — intervention group
Intervention type: OTHER
Intervention: Peripheral Blood Sample
Description: 30mL peripheral whole blood sample
Study NCT01553565 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cold polypectomy
Description: All colorectal polyps up to 10 mm found except for tiny hyperplastic polyps in the rectum and distal sigmoid colon are removed. The technique is cold resection of the polyp without tenting and then suction of the transected polyp into a trap followed by submission to histopathological evaluation.
Study NCT01553565 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cold polypectomy
Description: All colorectal polyps up to 10 mm found except for tiny hyperplastic polyps in the rectum and distal sigmoid colon are removed. The technique is cold resection of the polyp without tenting and then suction of the transected polyp into a trap followed by submission to histopathological evaluation.
Study NCT04438408 — intervention group
Intervention type: OTHER
Intervention: questionaires
Description: patients will answer to questionnaires on the quality of life and the control of the asthmatic disease as well as the therapeutic observance.
Study NCT03293745 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Face to Face CBT-I (F2F)
Description: CBT-I delivered in-person by the therapist.
Study NCT03293745 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemedicine CBT-I (TM)
Description: CBT-I delivered via American Academy of Sleep Medicine Telemedicine video conference System by the therapist.
Study NCT01712828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 25 mg Lenalidomide capsule will be administered orally once in the first period, and once with Quinidine in the second period
Study NCT01712828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinidine
Description: 300 mg of Quinidine will be administered orally every 12 hours for 1 day followed by 600 mg of Quinidine administered orally every 12 hours for the next 4 consecutive days
Study NCT01712828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: 25 mg/mL injection of Temsirolimus will be given directly into the vein over 30 minutes once in the second period and once with Lenalidomide in the third period.
Study NCT01712828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Just before Temsirolimus is given, 25 mg of Diphenhydramine (Benadryl) will be given directly into the vein to decrease chances of an allergic reaction to Temsirolimus.
Study NCT03627793 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: resistance training
Description: Moving muscles against loads with the purpose of increasing strength.
Study NCT03627793 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: resistance training
Description: Moving muscles against loads with the purpose of increasing strength.
Study NCT00484471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aripiprazole
Description: 15-30 mg/day aripiprazole, 22 weeks
Study NCT00484471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valproate
Description: sufficient dose as determined by investigator to maintain the therapeutic level.
Study NCT00484471 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: valproate
Description: sufficient dose as determined by investigator to maintain the therapeutic level.
Study NCT04481568 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PES-4-BPSD Model
Description: We will conduct a non-randomized preliminary efficacy trial, enrolling N=158 patients (79 control and 79 intervention). The primary outcome will be presence of BPSD as measured by a patient's total score on the Neuropsychiatric Inventory-Questionnaire (NPI-Q) during hospitalization. A multi-modal approach (including chart review and HCG questionnaires) will be used to determine the presence and severity of BPSD.
Study NCT00484471 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo to aripiprazole, 22 weeks
Study NCT03776474 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood collection
Description: Patients less than 5 kg : 2 ml Patients over 5 kg : 3 ml Patients over 10 kg : 5 ml
Study NCT04494269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegoprazan 50mg
Description: Oral administration once daily
Study NCT04494269 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tegoprazan 50mg
Description: Oral administration once daily
Study NCT03259152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab (trade names Prolia and Xgeva) is a human monoclonal antibody for the treatment of osteoporosis, treatment-induced bone loss, metastases to bone, and giant cell tumor of bone.Denosumab is a RANKL inhibitor, which works by preventing the development of osteoclasts which are cells that break down bone.
Study NCT04481568 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The attention control condition
Description: On this unit, the management of patients who display BPSD is performed by nurse assistants, rather than PES. Therefore, in order to test the added layer of PES staff, the nurse assistants on the control unit will receive equivalent dementia care education and training as well as staff support (please refer to NCT# 04179721 for more details on this aim).
Study NCT00917826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arginine Butyrate
Description: 1,000 mg/kg/day administered IV over 24 hours/day for 5 days (Days 1-5 of each 21 day cycle)
Study NCT00917826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganciclovir
Description: 5 mg/kg administered IV over 1 hour (Days 1-5 of each 21 day cycle)
Study NCT00917826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valganciclovir
Description: 900 mg BID for 16 days (Days 6-21 of each 21 day cycle)
Study NCT00798811 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: high-dose chemotherapy and autologous stem cell rescue
Description: Surgery -> enroll Pre-RT chemotherapy (2 cycles: A1, B1) PBSC collection during first cycle (A1) (2nd look surgery if necessary) RT (Reduced dose CSI) Post-RT chemotherapy (4 cycles: A2, B2, A3, B3) (if relapse or progression prior to HDCT, off study -> enroll S-083 protocol) HDCT1 (CTE) HDCT2 (CM)
Study NCT00798811 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: high-dose chemotherapy and autologous stem cell rescue
Description: Surgery pre-HDCT chemotherapy (6 cycles: A1, B1, A2, B2, A3, B3) PBSC collection during first cycle of chemotherapy (A1) (2nd look surgery if necessary) (if relapse or progression prior to HDCT, off study -> enroll S-083 protocol) HDCT1 (CTE) HDCT2 (CM) (RT if necessary) Observe
Study NCT02398669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorcaserin hydrochloride
Description: A single 10 mg dose of oral tablet formulation of lorcaserin hydrochloride will be administered with 240 mL of water.
Study NCT02655926 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deep Brain Stimulation
Description: Participants undergo implantation of bilateral electrodes at both the VS/VC and STN sites through a single burr hole under general anaesthesia. High-resolution MRI scans are used to calculate target coordinates and to verify accurate electrode location post-surgery. Each STN electrode have 4 electrical contacts at its distal tip (with a 0.5mm separation) and each VS/VC electrode have 4 electrical contacts at its distal tip (with a 1.5mm separation) to allow fine tuning of the exact site for stimulation delivery. Two non-rechargeable batteries (Activa PC) are connected to the electrodes and positioned under the skin of the right and left chest wall so that they correspond to the same set of electrodes for each patient: one for the 2 STN electrodes and one for the 2 VC/VS electrodes.
Study NCT00798811 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: high-dose chemotherapy and autologous stem cell rescue
Description: (Surgery if possible) Chemotherapy (4 cycles) PBSC collection during first cycle of chemotherapy during 4th cycle of chemotherapy (if BM involvement) (RT, if possible, after PBSC collection) (if less than PR prior to HDCT, off study) HDCT1 (CTE) HDCT2 (CM)
Study NCT03566277 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-monitoring
Description: Participants will have access to a wrist-worn activity monitor and have a daily step goal
Study NCT03566277 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentives
Description: Participants will have a deposit contract, wherein they will lose money if a goal is not reached, or double their money if a goal is reached
Study NCT03566277 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback
Description: Participants will receive text message feedback each day about progress towards their goal
Study NCT00873730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etanercept
Description: Etanercept 50 mg twice a week (BIW) for 12 weeks
Study NCT00873730 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etanercept/placebo
Description: Etanercept 50 mg once a week (QW) and placebo once a week for 12 weeks
Study NCT03679559 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Continue usual physical activity
Study NCT03679559 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention (home walking program and resistance training)
Description: Complete home-based walking program and resistance training
Study NCT03679559 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention (home-based Zumba program and resistance training)
Description: Complete home-based Zumba program and resistance training
Study NCT02656719 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided percutaneous tracheostomy
Description: Ultrasound guided percutaneous tracheostomy
Study NCT03679559 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention (HIIT program and resistance training)
Description: Complete HIIT program and resistance training